2160.T) announced today that its subsidiary, Gyre Therapeutics, Inc., received priority review status">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from GNI Group Ltd. was processed by Pulse News Wire on March 18, 2026. It represents a primary source document for Japanese Governance sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

GNI Group: Confirms F351 Receives Priority Review in China; Set to Submit Formal NDA Soon

TOKYO, Mar 18 (Pulse News Wire) – GNI Group Ltd. (2160.T) announced today that its subsidiary, Gyre Therapeutics, Inc., received priority review status from China's National Medical Products Administr

View all 2160.T disclosures →

Share this disclosure: Share on X Share on LinkedIn